CO6251249A2 - Un medicamento que comprende un derivado un derivado de carbostirilo y donepezilo para tratar enfermedad de alzheimer - Google Patents

Un medicamento que comprende un derivado un derivado de carbostirilo y donepezilo para tratar enfermedad de alzheimer

Info

Publication number
CO6251249A2
CO6251249A2 CO09145995A CO09145995A CO6251249A2 CO 6251249 A2 CO6251249 A2 CO 6251249A2 CO 09145995 A CO09145995 A CO 09145995A CO 09145995 A CO09145995 A CO 09145995A CO 6251249 A2 CO6251249 A2 CO 6251249A2
Authority
CO
Colombia
Prior art keywords
derivative
donepezil
salts
disease
salt
Prior art date
Application number
CO09145995A
Other languages
English (en)
Spanish (es)
Inventor
Heii Arai
Original Assignee
Otsuka Pharma Co Ltd
Univ Juntendo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd, Univ Juntendo filed Critical Otsuka Pharma Co Ltd
Publication of CO6251249A2 publication Critical patent/CO6251249A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CO09145995A 2007-05-22 2009-12-21 Un medicamento que comprende un derivado un derivado de carbostirilo y donepezilo para tratar enfermedad de alzheimer CO6251249A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007135367 2007-05-22

Publications (1)

Publication Number Publication Date
CO6251249A2 true CO6251249A2 (es) 2011-02-21

Family

ID=39636992

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09145995A CO6251249A2 (es) 2007-05-22 2009-12-21 Un medicamento que comprende un derivado un derivado de carbostirilo y donepezilo para tratar enfermedad de alzheimer

Country Status (27)

Country Link
US (1) US20100298375A1 (enExample)
EP (2) EP2157973B1 (enExample)
JP (1) JP5153870B2 (enExample)
KR (1) KR101441725B1 (enExample)
CN (1) CN101754758B (enExample)
AR (1) AR066664A1 (enExample)
AU (1) AU2008253977B2 (enExample)
BR (1) BRPI0811919A2 (enExample)
CA (1) CA2687289C (enExample)
CO (1) CO6251249A2 (enExample)
CY (1) CY1116683T1 (enExample)
DK (1) DK2157973T3 (enExample)
ES (1) ES2545959T3 (enExample)
HR (1) HRP20150843T1 (enExample)
HU (1) HUE025902T2 (enExample)
IL (1) IL202053A (enExample)
MX (1) MX2009012583A (enExample)
MY (1) MY146407A (enExample)
NZ (1) NZ581099A (enExample)
PL (1) PL2157973T3 (enExample)
PT (1) PT2157973E (enExample)
RU (1) RU2469723C2 (enExample)
SI (1) SI2157973T1 (enExample)
TW (2) TWI423802B (enExample)
UA (1) UA96633C2 (enExample)
WO (1) WO2008143361A1 (enExample)
ZA (1) ZA200908202B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
ES2665569T3 (es) 2011-03-01 2018-04-26 Pharnext Tratamiento de la isquemia cerebral
RU2015101100A (ru) * 2012-06-15 2016-08-10 Фаундейшн Фор Байомедикал Рисерч Энд Инновейшн Профилактическое и/или терапевтическое средство для умеренного когнитивного нарушения
US20160331922A1 (en) * 2013-12-23 2016-11-17 John W. Holaday Disposable container for air hydration
EP3459545A4 (en) 2016-05-19 2020-02-26 National Cerebral and Cardiovascular Center MEDICATION FOR PREVENTING AND / OR TREATING DEMENTIA
CN111032038A (zh) 2017-05-24 2020-04-17 H.隆德贝克有限公司 用于治疗阿尔茨海默氏病的药物组合
CN107602523B (zh) * 2017-09-11 2020-08-18 安徽中医药大学 京尼平类似物、制备方法及其应用
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5649378A (en) 1979-08-25 1981-05-02 Otsuka Pharmaceut Co Ltd Tetrazolylalkoxycarbostyril derivative
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2574099B2 (ja) 1992-05-21 1997-01-22 大塚製薬株式会社 アレルギー疾患治療剤
JPH10175864A (ja) 1996-12-16 1998-06-30 Otsuka Pharmaceut Co Ltd 慢性閉塞性肺疾患治療剤
US6428488B1 (en) * 1997-08-28 2002-08-06 Kenneth Kensey Dual riser/dual capillary viscometer for newtonian and non-newtonian fluids
US6322525B1 (en) * 1997-08-28 2001-11-27 Visco Technologies, Inc. Method of analyzing data from a circulating blood viscometer for determining absolute and effective blood viscosity
US6019735A (en) * 1997-08-28 2000-02-01 Visco Technologies, Inc. Viscosity measuring apparatus and method of use
US6322524B1 (en) * 1997-08-28 2001-11-27 Visco Technologies, Inc. Dual riser/single capillary viscometer
ES2237078T3 (es) * 1998-01-16 2005-07-16 Eisai Co., Ltd. Procedimiento para producir derivados de donepezilo.
US6187790B1 (en) * 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6484565B2 (en) * 1999-11-12 2002-11-26 Drexel University Single riser/single capillary viscometer using mass detection or column height detection
US6458804B1 (en) * 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
TW200301135A (en) * 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
IL150509A (en) * 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
US6743806B2 (en) * 2002-10-23 2004-06-01 Otsuka Pharmaceutical Company, Limited Active oxygen scavenger
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
JP2004189706A (ja) * 2002-12-13 2004-07-08 Eisai Co Ltd 高度アルツハイマー型痴呆治療剤
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener

Also Published As

Publication number Publication date
AU2008253977B2 (en) 2013-08-22
ZA200908202B (en) 2010-07-28
MX2009012583A (es) 2010-03-08
HRP20150843T1 (hr) 2015-09-11
KR20100020482A (ko) 2010-02-22
EP2937085A1 (en) 2015-10-28
US20100298375A1 (en) 2010-11-25
CA2687289C (en) 2015-09-15
TWI423802B (zh) 2014-01-21
RU2469723C2 (ru) 2012-12-20
WO2008143361A1 (en) 2008-11-27
AU2008253977A1 (en) 2008-11-27
TWI489983B (zh) 2015-07-01
NZ581099A (en) 2012-03-30
RU2009147456A (ru) 2011-06-27
AR066664A1 (es) 2009-09-02
EP2157973B1 (en) 2015-07-15
KR101441725B1 (ko) 2014-09-18
TW200904428A (en) 2009-02-01
JP5153870B2 (ja) 2013-02-27
EP2937085B1 (en) 2019-07-10
CN101754758A (zh) 2010-06-23
PT2157973E (pt) 2015-10-14
IL202053A (en) 2016-04-21
EP2157973A1 (en) 2010-03-03
BRPI0811919A2 (pt) 2014-11-18
DK2157973T3 (en) 2015-08-17
SI2157973T1 (sl) 2015-10-30
IL202053A0 (en) 2010-06-16
UA96633C2 (uk) 2011-11-25
MY146407A (en) 2012-08-15
TW201412315A (zh) 2014-04-01
CN101754758B (zh) 2012-10-24
PL2157973T3 (pl) 2015-12-31
CA2687289A1 (en) 2008-11-27
CY1116683T1 (el) 2017-03-15
HUE025902T2 (en) 2016-05-30
HK1140422A1 (en) 2010-10-15
ES2545959T3 (es) 2015-09-17
JP2010527993A (ja) 2010-08-19
HK1215384A1 (en) 2016-08-26

Similar Documents

Publication Publication Date Title
CO6251249A2 (es) Un medicamento que comprende un derivado un derivado de carbostirilo y donepezilo para tratar enfermedad de alzheimer
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112015019720A2 (pt) inibidores de (benzil-ciano-metil)-amidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c
ECSP14006132A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
BR112014008686A2 (pt) derivados de oxazina e uso dos mesmos no tratamento de doença
AR059948A1 (es) Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa
SV2010003491A (es) 2- anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
BR112015006055A2 (pt) composições e métodos para o tratamento e prevenção de lesão tecidual e doença
AR076400A1 (es) Formulaciones liquidas de sales de 1-(2-(2,4-dimetilfenilsulfanil)fenil)piperazina, uso, la sal y recipiente
AR104068A1 (es) Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
PE20110711A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmaceuticamente aceptables de la misma
MX370361B (es) Preparación farmacéutica que contiene compuesto de ácido piridilaminoacético.
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
AR067446A1 (es) Un medicamento para tratar higado graso que comprende cilostazol
BR112015002390A2 (pt) compostos
EP2796450A4 (en) 6-AMINOPYRIDIN-3-OL DERIVATIVES OR PHARMACEUTICAL SALTS AND / OR PHARMACEUTICAL COMPOSITION THEREOF AS ACTIVE AGENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES
AR097997A1 (es) Composición farmaceutica de ibuprofeno y tramadol para uso oftálmico
MX384072B (es) Compuesto derivado de pirrolo-piridina, metodo para preparar el mismo y composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o el tratamiento de enfermedades relacionadas con la proteina cinasa.
ES2397638R1 (es) Soluciones antisepticas de un derivado de di (4-cloro-fenildiguanido) y sus procedimientos

Legal Events

Date Code Title Description
FG Application granted